Which has the lower trailing P/E, ASND or EXEL?

ASND has the lower trailing P/E: ASND trades at 17.33 and EXEL at 18.45. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ASND or EXEL?

Over the past five years, ASND grew revenue faster — ASND at a 189.92% CAGR versus EXEL at 16.06%.

Is ASND or EXEL more profitable?

ASND runs the higher net margin — ASND at 71.08% versus EXEL at 35.33%.

How have ASND and EXEL total returns compared?

Over the past 10 years, ASND delivered 27.41% and EXEL delivered 16.20% annualized total return. Past performance doesn't predict future results.

Ascendis Pharma A/S (ASND) vs Exelixis, Inc. (EXEL)

A side-by-side comparison of Ascendis Pharma A/S and Exelixis, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ASND

Ascendis Pharma A/S

$14.16B

$228.03HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

EXEL

Exelixis, Inc.

$14.79B

$58.85HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ASND vs EXEL

growth of $100 · dividends reinvested · last 10y

ASND +1027.2% (+27.4%/yr)EXEL +280.2% (+14.3%/yr)ASND compounded faster over this window

ASND EXEL

ASND vs EXEL: by the numbers

•EXEL is the larger company ($14.79B vs $14.16B market cap).
•ASND trades at the lower trailing earnings multiple (17.33 vs 18.45 P/E), one valuation lens rather than an overall verdict.
•ASND converts more revenue to profit (71.08% vs 35.33% net margin).
•ASND grew revenue faster over the past five years (189.92% vs 16.06% CAGR).

Metrics side by side

Valuation

Metric	ASND	EXEL
P/E ratio	17.33	18.45
Forward P/E	N/A	16.75
PEG ratio	N/A	0.36
P/S ratio	11.59	6.07
P/B ratio	8.64	8.02
EV / EBITDA	93.79	14.68
FCF yield	2.73%	7.83%

Profitability

Metric	ASND	EXEL
Gross margin	90.18%	96.48%
Operating margin	-18.92%	39.88%
Net margin	71.08%	35.33%
ROE	52.97%	46.68%
ROIC	5.85%	37.87%

Growth (annualized)

Metric	ASND	EXEL
Revenue CAGR (5Y)	189.92%	16.06%
EPS CAGR (5Y)	N/A	51.51%
FCF CAGR (5Y)	N/A	39.63%
Total return CAGR (5Y)	7.40%	23.00%

Frequently asked

Which has the lower trailing P/E, ASND or EXEL?: ASND has the lower trailing P/E: ASND trades at 17.33 and EXEL at 18.45. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ASND or EXEL?: Over the past five years, ASND grew revenue faster — ASND at a 189.92% CAGR versus EXEL at 16.06%.
Is ASND or EXEL more profitable?: ASND runs the higher net margin — ASND at 71.08% versus EXEL at 35.33%.
How have ASND and EXEL total returns compared?: Over the past 10 years, ASND delivered 27.41% and EXEL delivered 16.20% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ASND analysis Full EXEL analysis Interactive comparison tool

Dig into the metrics

Ascendis Pharma A/S P/E ratio Exelixis P/E ratio Ascendis Pharma A/S ROE Exelixis ROE Ascendis Pharma A/S operating margin Exelixis operating margin Ascendis Pharma A/S revenue growth Exelixis revenue growth Ascendis Pharma A/S free cash flow Exelixis free cash flow

Ascendis Pharma A/S & Exelixis appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.